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responsible for around 2–5% of total hypertensive population.
Among patients with renovascular hypertension (RVH), incidence
of atherosclerotic renal artery stenosis (ARAS) is about 80–90%,
whereasﬁbromusculardysplasia (FMD) is responsible only foraround
10% patients. Intimal ﬁbroplasia occurs in less than 10% of all the
patients with FMD.We report a rare case of 28-year-old ladywho had
newly detected hypertension during 12th week of pregnancy later
leading to intra-uterinedeathof the fetusat28weeksofgestation,and
then she was referred to us for evaluation and management and
found to have intimal ﬁbromuscular dysplasia of renal artery, which
was treated successfully with percutaneous intervention.
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Background: Distal embolization of thrombus during primary PCI
results into reduced myocardial perfusion and poor clinical out-
comes. The objective of our study was to assess the role of manual
thrombus aspiration to improve myocardial perfusion occur dur-
ing primary PCI.
Methods: Single center prospective observation study was under-
taken in a tertiary care hospital. Study was carried out on 104
number of patients presented with STEMI of <12 h duration. Of
which, 52 underwent primary PCI with thrombus aspiration and
remaining were opted for conventional primary PCI. Angiographic
and electrocardiographic signs of myocardial perfusion, as well as
clinical outcomes were assessed. The primary end was corrected
TIMI frame count (cTFC) and secondary end points were ST seg-
ment resolution and mortality at 30 days and 6 months.
Results: A cTFC of<30 occurred in 94.23% of patients in primary PCI
with thrombus aspiration group and in 86.53% falling under con-
ventional primary PCI group (p < 0.001). Also a trend was observed
indicating lower incidence of slow or no reﬂow in patients treated
with primary PCI with thrombus aspiration vis-a-vis conventional
primary PCI (3.84% vs 9.61%, p = 0.01). Complete resolution of ST-
segment elevation (>70% ST resolution) occurred in 59.34% and
46.12% patients, respectively (p < 0.005). Further analysis revealed
thatmortality beneﬁtwasnot conferredat 30 days (1.92%and3.84%,
p = 0.21) and 6months (3.84% and 7.69%, p = 0.13) in both the groups.
Conclusion: Our study showeda trend towards improvedmyocardial
perfusion (cTFC and ST segment resolution) with manual thrombus
aspiration during primary PCI as compared to conventional primary
PCI. However, mortality beneﬁt was not conferred with thrombus
aspiration when compared with conventional primary PCI.
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Background: First generation DES, including SES (Sirolimus eluting
stents), have signiﬁcantly reduced rates of re-stenosis and TLR
compared with BMS. But, at the same time, they have been found
to be associated with increased rates of late and very late stent
thrombosis, as well as MI. Improved stent designs with thinner
struts and more biocompatible polymer coatings and optimized
drug elution proﬁles (EES – everolimus-eluting stents) might favor-
ably inﬂuence DES performance. The aim to the study was to test
whether EES prevents clinical ischemic events better as compared
to SES.
Methods: We enrolled 120 patients with a diagnosis of ACS
(NSTEMI or STEMI) who had SVD (discrete lesion in culprit vessel)
on CAG over a 12-month period. Patients were assigned into EES or
SES group. Primary end points studied were CV Death and ACS;
Stent thrombosis and symptomatic in-stent re-stenosis (h/o
Chronic Stable Angina Post-PTCA +50% Late Lumen Loss on CAG).
Results: Incidence of CV death and ACS was 5% and 8.88% in EES
and SES group respectively ( p < 0.05), while that of Stent throm-
bosis was 3.33% and 6.66% ( p < 0.05). When studied in diabetic
subgroup, incidence of CV Death and ACS was 4% and 11.53%
( p < 0.05). Incidence of symptomatic ISR was 3.33% and 6.66% in
the two groups. In the diabetic subgroup, incidence of sympto-
matic ISR was 4% and 7.7%.
Conclusions: Our results support the hypothesis that the safe and
efﬁcacious platform of EES ismore effective in preventing ischemic
events (including stent thrombosis), and ISR than SES (1st genera-
tion DES). The results were in favor of EES when studied in context
of diabetic subgroup as well.
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Sirolimus-eluting stent (SES) is a ﬁrst-generation drug-eluting
stent (DES) and everolimus-eluting stent (EES) is a second genera-
tion drug-eluting stent. These both DES are widely used and most
extensively studied stents. Use of a DES substantially reduces
restenosis after coronary stent implantation; however, late
adverse events like stent thrombosis (ST) and late in-stent rest-
enosis (ISR) requiring target-lesion revascularization (TLR) occur-
ring beyond 1 year are still a problem. Similar outcomes have been
reported in various recent randomized trials comparing EES and
SES.
In this study, retrospective cohort study was done in the patients
who underwent stent implantation using SES or EES in Dhiraj
Hospital, Vadodara. Comparison between SES and EES was done
in patients who presented for follow-up in our cardiology depart-
ment over one year, i.e. May 2014 to May 2015 after their angio-
plasty. Based on angiographic and clinical outcome in terms of late
ST and ISR requiring TRL, outcome variables were set. The study
was carried out for evaluating non-inferiority of EES as compared
to SES in terms of late ST and ISR requiring TRL.
A total of 136 patients who underwent stent implantation using
SES or EES one to one and half year back agreed to be part of our
study and constituted our cohort. Out of these 136 patients, 60 had
SES implantation and 76 had EES implantation. All of these
patients were subjected to coronary angiography after 1 year to
look for patency of the stent. In-stent restenosis (outcome) was
found in 3 patients in SES group and 4 patients in EES group,
respectively.
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The back records of the time of their angioplasty (at time of
presentation) were tracked and referred. Average age of the study
population was found to be 58.7 years (SD: 9.2 years, ranging 29–79
years, comprising 97 males and 39 females). Mean age of patients
with ST and ISR requiring TLR was 61.8 years and without stent
restenosis was 58.3 years. All 7 patients who had ISRwere suffering
from diabetes and hypertension. Association between diabetes and
ISR (Chi square = 5.488; p = 0.01; considering 95% CI) and hyperten-
sion & ISR (Chi square = 6.756; p = 0.00) is signiﬁcant.While compar-
ing the two stents: everolimus-eluting and sirolimus-eluting
coronary stentswith theoutcome, i.e., in-stent restenosis and target
lesion revascularization (Chi square = 0.005; p = 0.94)with 95%CI, no
signiﬁcant difference between the two stents was found. Hence the
null hypothesis, that there is no signiﬁcant difference between use
of everolimus-eluting and sirolimus-eluting coronary stents on
clinical and angiographic follow-up is accepted.
Therefore EES implantation was non-inferior to and had similar
results to SES implantation after one year in terms of clinical and
angiographic outcome. Both the SES and EES groups showed a
similar efﬁcacy and excellent outcome after one year with a very
low rate of in-stent restenosis, stent thrombosis, and target-lesion
revascularization.
Non-right coronary sinus origin right
coronary artery intervention: Our
experience over 3 years
Arindam Pande *, Rabin Chakraborty
Apollo Gleneagles Hospital, Kolkata, India
Non-right coronary sinus origin RCA interventions are technically
demanding. Proper selection of hardware is the key to success.
Over last 3 yearswehad total 16 such interventions (7 RCA from left
coronary sinus and 9 from non-coronary sinus). RCA from Left-
coronary cusp were more difﬁcult to engage than non-coronary
cusp. Mean ﬂuoroscopic time (22.6 min [11.6–66.5] vs 16.5 min
[13.4–38.6]) as well as mean volume of contrast used (206 ml
[112–322] vs 168 ml [110–280]) were both higher in left coronary
sinus origin RCA interventions. In our series, RCA from non-cor-
onary cusp were most frequently engaged with AR guiding cathe-
ter whereas RCA from left-coronary cusp were most frequently
engaged with JL guiding catheter.
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Introduction: Management of coronary artery in-stent restenosis
(ISR) is a challenging as well as debatable topic. Options include
plain old balloon angioplasty (POBA), metallic stent, cutting or
scoring balloon and drug-eluting balloon (DEB). All the techniques
have their own advantages and drawbacks. Till date the optimum
treatment strategy is undeﬁned.
Methods and results: In the current series we implanted ﬁve
bioresorbable vascular scaffolds (BVS) in ISR over a period of 1
year. Most of the procedures were guided by intravascular imaging
(OCT in 2 cases and IVUS in 1 case). The patients were followed up
subsequently (for amean period of 5months). All the patientswere
symptom free till date. No repeat target vessel revascularization
had to be performed.
Discussion: BVS is the latest advance in the armamentarium of
interventional therapies for treating de novo signiﬁcant coronary
artery disease. Recent data from trials have suggested many
advantages of BVS over DES. The rationale of using BVS in ISR is
based on the concept of local drug delivery as achieved by DEBwith
the beneﬁts of a scaffold to stabilize dissection ﬂaps, and prevent
acute recoil as provided by metallic stent, without the permanent
bi-layer of metal, that in some vessels, may in and by itself create
ﬂow abnormality.
Conclusion: BVS based treatment strategy for ISR have appealing
biologic advantage. Efﬁcacy and outcomes of this new therapeutic
option need to be evaluated in comparison to other established PCI
based therapies, such as repeat metallic stent implantation, in a
randomized setting.
An interesting case report of coronary
artery perforation following PCI
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Background: Coronary artery perforation is a rare complication of
PCI with a reported incidence of 0.2–0.6%. Development of peri-
cardial tamponade has been associated with a high mortality. We
present a report of one such patient highlighting the key learning
points from the case.
Case Report: A 69-year-old male admitted with a history of angina
equivalent since 2 months, CAG done revealed signiﬁcant proximal
LADcomplexbifurcation lesion. PTCA/stent tomid todistal LADwas
done using 3.0–2.5 mm  60mm BIOMIME MORPH DES. Post-stent-
ingpatient developed suddenhypotensionandasystole.Angiogram
revealed coronary leak with dye staining of pericardial sac and 2D
Echo showed gross pericardial ﬂuid collection suggestive of tampo-
nade. Pericardiocentesis was done via pigtail catheter and the aspi-
rated blood was autotransfused via the femoral vein. Patient was
intubated, started on inotropes. His vitals stabilized transiently but
within minutes patient once again became hypotensive and devel-
opedbradycardia. Echorevealedgross reaccumulationofpericardial
ﬂuid. Pericardiocentesis and autotransfusion was done repeatedly.
CAG revealed a persistent signiﬁcant leak from the mid part of the
LAD stent. A 3 mm  16 mm coronary covered stent was placed in
stent in the mid-LAD, which effectively sealed the leak. Pericardio-
centesis and auto transfusion was repeated post procedure. Patient
was stabilized and shifted to ICCU. Serial repeat 2D Echo did not
reveal any reaccumulation of ﬂuid in pericardial sac. Patient was on
ventilator for 72 h due to neurological impairment and was started
on neuroprotective agents by neurophysician. He showed gradual
improvement, was extubated and shifted to theward after 7 days in
ICU. With regular physiotherapy, rehabilitation and optimal med-
ications, patient recovered well with minimal residual neurological
deﬁcit. He was discharged after 15 days and is hemodynamically
stable on regular follow-up.
Conclusion: Pericardial tamponade due to coronary artery perfora-
tion has a high mortality. Surgical intervention has been cited as
the only life-saving option in such cases. Expertise in the use of
covered stents may provide a quick and valuable rescue option for
this serious complication.
A single center experience of device
closure for ventricular septal rupture in
acute myocardial infarction
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Background: Post-infarction ventricular septum rupture (VSR) is a
rare mechanical complication of an acute myocardial infarction
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